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2 
ABSTRACT 24 
 25 
Bluetongue is one of the major infectious diseases of ruminants and is caused by 26 
Bluetongue virus (BTV), an arbovirus existing in nature in at least 26 distinct serotypes. Here, 27 
we describe the development of a vaccine platform for BTV. The advent of synthetic biology 28 
approaches and the development of reverse genetics systems, has allowed the rapid and 29 
reliable design and production of pathogen genomes which can be subsequently 30 
manipulated for vaccine production. We describe BTV vaccines based on “synthetic” viruses 31 
in which the outer core proteins of different BTV serotypes are incorporated into a common 32 
tissue-culture adapted backbone. As a means of validation for this approach, we selected 33 
two BTV-8 synthetic reassortants and demonstrated their ability to protect sheep against 34 
virulent BTV-8 challenge. In addition, to further highlight the possibilities of genome 35 
manipulation for vaccine production, we also designed and rescued a synthetic BTV chimera 36 
containing a VP2 protein including regions derived from both BTV-1 and BTV-8. 37 
Interestingly, while the parental viruses were neutralized only by homologous antisera, the 38 
chimeric proteins could be neutralized by both BTV-1 and BTV-8 antisera. These data 39 
suggest that neutralizing epitopes are present in different areas of the BTV VP2 and likely 40 
“bivalent” strains eliciting neutralizing antibodies for multiple strains can be obtained.  41 
Importance 42 
Overall, this vaccine platform can significantly reduce the time taken from the identification 43 
of new BTV strains to the development and production of new vaccines, as the viral 44 
genomes of these viruses can be entirely synthesised in vitro. In addition, these vaccines can 45 
be brought quickly in the market as they alter the approach, but not the final product, of 46 
3 
existing commercial products.   47 
 48 
49 
4 
INTRODUCTION 50 
Bluetongue is a major infectious disease of ruminants and is caused by Bluetongue virus 51 
(BTV), an arbovirus in the Reoviridae family transmitted from infected to uninfected 52 
mammalian hosts by Culicoides biting midges (1, 2).  53 
BTV has a genome composed of ten linear double-stranded RNA (dsRNA) segments 54 
encoding for seven structural and four non-structural proteins (3-5).  The BTV virion is an 55 
icosahedral particle assembled as a triple layered capsid (6, 7). There are at least 26 BTV 56 
serotypes (BTV-1 to BTV-26) circulating worldwide. Serotypes are determined primarily by 57 
differences in the outer capsid protein VP2, which mediates viral entry into the cell and is 58 
the target for neutralizing antibodies in infected animals (8-13). VP2, and to a lesser extent 59 
VP5, interact with the VP7 protein, the major component of the underlying core (14).  60 
BTV infection in mammalian hosts results in inapparent to severe clinical symptoms 61 
generally associated with damage to small blood vessels (2, 15, 16). Serotype-specific 62 
neutralizing antibodies are generated upon infection in both naturally or experimentally 63 
infected ruminants and provide little or no protection against heterologous serotypes (17, 64 
18). 65 
Traditionally, bluetongue endemic regions have been limited to tropical and sub-tropical 66 
areas of the world (19, 20). However, in the last 15 years, similarly to some other arbovirus 67 
infections, bluetongue has expanded its geographical limits. Since 1998, outbreaks caused 68 
by various BTV serotypes have been increasingly observed in Northern Africa and Europe 69 
(21-23). 70 
Vaccination of susceptible livestock remains the most effective strategy for the control of 71 
BTV epidemics. Currently, only two different types of vaccines are available commercially:  72 
live attenuated vaccines, traditionally obtained from the successive passage of BTV in 73 
5 
embryonated eggs or tissue culture, and inactivated whole-virus vaccines, in which BTV 74 
viruses are grown in tissue culture and later chemically inactivated.  75 
Live attenuated vaccines have been used for decades in South Africa where Bluetongue is 76 
endemic (24). These vaccines elicit strong neutralizing antibody and likely cell-mediated 77 
immune responses and confer long term protection against homologous BTV infection (18). 78 
However, their use in Southern Europe, although effective in most cases, has been a cause 79 
of concern as some strains have been proven to be (i) poorly attenuated, (ii) teratogenic and 80 
affecting pregnancy, (iii)  transmitted to non-vaccinated animals and (iv) reassorted with 81 
wild type viruses (25-29). For these reasons, the use of live attenuated viruses for BTV 82 
control in Europe was discontinued and several vaccine manufacturers developed whole-83 
virus inactivated vaccines (18, 30). These vaccines were proven to protect vaccinated 84 
animals against homologous BTV challenge. Although the duration of immunity induced by 85 
inactivated vaccines is shorter compared to that induced by live vaccines, their use helped 86 
to control and eventually eliminate BTV-1 and BTV-8 from Central and Northern Europe (18, 87 
31-33).  88 
The advent of synthetic biology approaches and the development of reverse genetics 89 
systems, has allowed the rapid and reliable design and production of pathogen genomes 90 
which can be subsequently manipulated for vaccine production. In the present study, we 91 
describe the development of a strategy for the design and production of inactivated BTV 92 
vaccines that can significantly reduce the time taken from the identification of a new BTV 93 
emerging strain, to the development and production of a new vaccine.  94 
 95 
 96 
6 
MATERIALS AND METHODS 97 
Cells. BSR, VERO and BHK21 cells were grown in Dulbecco’s modified Eagle’s medium 98 
(DMEM) supplemented with 5% fetal bovine serum (FBS). Cells were incubated at 35oC or 99 
37°C, depending on the experimental setting, in a humidified incubator with 5% CO2. BSR 100 
cells were used for the recovery of "synthetic" BTV (sBTV) reassortants  (5, 36). BHK21 cells 101 
were used for the production of BTV reassortants according to industry practice (20, 32), 102 
while VERO cells are cells recommended by the OIE (World Animal Health Organization) for 103 
the diagnosis of BTV infection in ruminants by seroneutralization assays (34). 104 
Plasmids. Plasmids used for the rescue of BTV-1 of BTV-8 by reverse genetics were 105 
described previously (4). Similar plasmids containing segment 2 (encoding for VP2) or 106 
segment 6 (encoding VP5) of the reference strains of BTV-2 to -24 and the recently 107 
described BTV-25 and -26 were synthesized commercially (Genscript) (Table 1). In addition, 108 
a chimeric BTV-1/BTV-8 segment 2 was also synthesised in which the nucleotide sequence 109 
encoding amino acid residues 220 to 429 of the BTV-8 VP2 were introduced into the 110 
homologous region of the BTV-1 segment 2. 111 
Recovery of "synthetic" BTV (sBTV) reassortants. Synthetic BTV reassortants were rescued 112 
in vitro by reverse genetics as previously described (4, 35). Briefly, DNA plasmids containing 113 
the eight genomic segments of the BTV-1 backbone and each of the segments 2 and 6 of the 114 
26 different BTV serotypes were linearized with restriction enzymes and purified by phenol-115 
chloroform extraction. The linearized plasmids were then used as templates for the in vitro 116 
synthesis of capped BTV-like RNA using mMESSAGE mMACHINE T7 Ultra Kit (Ambion), 117 
following the manufacturer’s instructions. RNA was then extracted by phenol-chloroform 118 
and further purified using the RNeasy Mini Kit (Qiagen). For the rescue of synthetic BTV 119 
virus, monolayers of BSR cells in 12-well plates were transfected twice with BTV RNAs using 120 
7 
Lipofectamine 2000. Firstly, 1x1011 RNA molecules of each segment encoding VP1, VP3, 121 
VP4, NS1, VP6 and NS2 were diluted in Opti-MEM I Reduced Serum Medium containing 122 
0.5U/µl of RNAsin Plus (Promega) for 5 min and mixed with Lipofectamine 2000 diluted in 123 
Opti-MEM I Reduced Serum Medium. After 25 min of incubation at room temperature, the 124 
mixture was added drop-wise to the cells and transferred to a humidified incubator at 35C. 125 
After 16-18h a second transfection was carried out using 1x1011 molecules of all the BTV 126 
segments. sBTVs were plaque purified from supernatants of transfected cultures displaying 127 
cytopathic effect. Viruses obtained by reverse genetics based on the reference strain of BTV-128 
1 from South Africa and the European BTV-8 strain (NET2006/04) were described previously 129 
(4). Each sBTV reassortant is formed by a "backbone" (i.e. all the non-structural and 130 
enzymatic proteins in addition to VP7 and VP3) of BTV-1 and an outer capsid layer 131 
comprising VP2 and VP5 (or only the VP2) of a heterologous serotype. Each synthetic virus is 132 
referred in this study with "B1" (indicating the backbone of BTV-1), followed by the serotype 133 
of the VP2 (encoded by Seg-2) and VP5 (encoded by Seg-6) combination used. For example, 134 
B1BTV-8
VP2/VP5 is a synthetic virus containing the backbone of BTV-1 with the VP2 and VP5 of 135 
BTV-8. Synthetic reassortants with a heterologous VP2 - VP5 combination have an additional 136 
number referring to the serotype from which the VP5 was obtained. For example, B1BTV-137 
24VP2(4-VP5) has the backbone of BTV-1, the VP2 from BTV-24 and the VP5 from BTV-4. An 138 
additional synthetic BTV was rescued incorporating the chimeric BTV-1/BTV-8 VP2 segment 139 
and designated as B1BTV-1
(8-VP2-220-429).  140 
sBTV plaque phenotype and replication kinetics. Viral plaque phenotypes of each sBTV 141 
reassortant were assessed in VERO cells. Cell monolayers were infected with 10-fold viral 142 
dilutions in DMEM for 2 h at 37°C, after which media containing the virus was removed, the 143 
cells washed with PBS, followed by incubation with 3 ml of media containing 1.2% Avicel® 144 
8 
(FMC Biopolymer) at 37°C for 72 h. Plates were fixed with 4% formaldehyde for 1 h. The 145 
monolayer was incubated with a primary rabbit antibody against the BTV VP7 protein (4), 146 
followed by an anti-rabbit HRP-conjugated secondary antibody and finally stained with 147 
TrueBlue™ peroxidase staining kit (KPL). The replication kinetics of each synthetic virus was 148 
assessed in BHK21 cells as already described (4) using an MOI of 0.001.  149 
Inactivated vaccine production. B1BTV-8
VP2/VP5 and B1BTV-8
VP2 were grown for 48 h in BHK21 150 
cells in 50 l bioreactors at 37°C in 5% CO2 humidified atmosphere at the Merial S.A.S. 151 
laboratory using standard industrial procedures. Prior to inactivation, virus cultures were 152 
treated with chloroform, mechanically homogenised with Ultra-Turrax T50 (IKA), clarified by 153 
filtration and centrifugation. Formaldehyde (0.5mg/ml) was then added to the filtrated 154 
supernatant, which was subsequently treated twice with binary ethyleneimine (1.5 mM). 155 
This inactivation step was carried out at 37oC for 24h. Complete inactivation of the virus was 156 
confirmed by serially passaging the treated supernatants three times in VERO cells. The 157 
inactivated supernatant was filtrated in high flow capacity filters, concentrated twice and 158 
purified by immobilized metal ion affinity chromatography. Antigen dosage was then 159 
measured through dot-blot analysis of the VP2 protein in parallel with an ELISA for the VP7 160 
protein in order to use amounts of antigen identical to the commercial BTVPUR AlSap® 161 
vaccines (30). Vaccines were blended with aluminium hydroxide  and saponin. 162 
Vaccination and BTV challenge. All animal experiments were carried out in accordance with 163 
EU legislation and conducted in a high containment animal facility. 4 to 5 months old 164 
Lacaune crossbred sheep, confirmed to be seronegative for BTV-8 by serum neutralisation 165 
at the beginning of the study, were divided into four groups: G1 (n=6) was the unvaccinated 166 
control, G2 (n=5) was vaccinated with B1BTV-8
VP2/VP5, G3 (n=5) was vaccinated with B1BTV-167 
9 
8VP2 and G4 (n=5) was vaccinated with a low antigen dose (1/10th compared to the dose 168 
used in G3) of B1BTV-8
VP2. Sheep were vaccinated subcutaneously with a single dose of 1 ml 169 
of each sBTV vaccine while control sheep were not vaccinated.  170 
21 days after vaccination, individual rectal temperatures were recorded and serum samples 171 
were collected before sheep were challenged intradermally with 3ml of a virulent North 172 
European BTV-8 strain (1x107 genome copy number/ml) distributed among approximately 173 
30 separate injection points. Sheep were monitored daily up to 14 days post-challenge for 174 
rectal temperature and clinical signs (general and body condition, congestion and/or 175 
oedema, hypersalivation, nasal discharge/crusts, plaintive bleating, swollen lymph nodes, 176 
locomotion difficulty, respiratory and digestive problems). A clinical score was assigned for 177 
the following signs: between 0 and 3 for general condition, 0 and 1 for body condition and 0 178 
to 4 for hyperthermia defined as body temperature above 40°C. Any other clinical signs 179 
scored 1 if present. The individual scores for each sheep were added together, resulting in a 180 
daily clinical score. Blood samples were collected on days 5, 7, 9, 12 and 14 post-challenge in 181 
order to detect BTV RNA as an indication of viremia by qRT-PCR (see below). Neutralising 182 
antibody titres in the serum of each animal were also measured at day 14 post-challenge 183 
(see below). 184 
Neutralization assays. The presence of neutralizing antibodies in vaccinated and control 185 
sheep was assessed by microneutralization assays as already described (36). Sera were 186 
collected at the beginning of the study before vaccination (-21 days), at the time of BTV-8 187 
challenge (Day 0) and 2 weeks post-challenge (Day 14). The 50% protective dose (PD50) for 188 
each serum sample, defined as the serum dilution that inhibits BTV infection in 50% of VERO 189 
cell cultures, was then determined using a linear regression after angular transformation. 190 
Samples below the detection limit of 0.48 Log10 PD50 were considered negative. 191 
10 
Quantitative RT-PCR. RNA was extracted from blood samples using the QIAamp Viral RNA 192 
Mini Kit (Qiagen) according to the manufacturer’s instructions. One-step quantitative RT-193 
PCR for the amplification of a conserved region of segment 10 was performed using TaqMan 194 
EZ RT-PCR core reagent (Applied Biosystems). Serial ten-fold dilutions of RNA standard in 195 
vitro transcribed from the BTV segment 10 were used to obtain a standard curve.  196 
197 
11 
RESULTS 198 
Rescue of synthetic BTV viruses (sBTV). We obtained DNA plasmids containing 199 
commercially synthesised genomic segments encoding VP2 and VP5 (outer core proteins) of 200 
the reference strains of BTV-1 to -26. Plasmids were designed in order to be used in BTV 201 
rescue experiments as already described (4, 35). Initially, cells were transfected using 202 
homologous Seg-2 and Seg-6 from each serotype, in addition to plasmids containing 203 
genomic segments forming the “backbone” of the synthetic viruses (Seg-1, -3, -4, -5, -7, -8, -204 
9 and -10) encoding the remaining structural, enzymatic and non-structural proteins from 205 
BTV-1. The above strategy was successful for the rescue of 16 different BTV serotypes 206 
resulting in the generation of the following synthetic BTV viruses: B1BTV-1
VP2/VP5, B1BTV-207 
2VP2/VP5, B1BTV-3
VP2/VP5, B1BTV-4
VP2/VP5, B1BTV-6
VP2/VP5, B1BTV-8
VP2/VP5, B1BTV-9
VP2/VP5, B1BTV-208 
11VP2/VP5, B1BTV-13
VP2/VP5, B1BTV-17
VP2/VP5, B1BTV-20
VP2/VP5, B1BTV-21
VP2/VP5, B1BTV-22
VP2/VP5, 209 
B1BTV-23
VP2/VP5, B1BTV-25
VP2/VP5 and B1BTV-26
VP2/VP5. Seg-2 and Seg-6 of BTV-25 were 210 
synthesised using the untranslated regions of the homologous segments of BTV-1.  211 
For those synthetic viruses that we were not able to rescue using homologous VP2 and VP5, 212 
we attempted rescue experiments using each Seg-2 (encoding VP2) in combination with the 213 
remaining 25 heterologous Seg-6 (encoding VP5). Following this approach, two new sBTV 214 
were generated: B1BTV-14
VP2(6-VP5), rescued using the VP2 of BTV-14 and the VP5 of BTV-6, 215 
and B1BTV-24
VP2(4-VP5), rescued using the VP2 of BTV-24 and the VP5 of BTV-4. Other 216 
strategies used to rescue the synthetic viruses with the outer core proteins of BTV-5, BTV-7, 217 
BTV-10, BTV-12, BTV-15, BTV-16, BTV-18 and BTV-19 included the use of Seg-2 with the 218 
untranslated region of BTV-1 and the use of homologous VP2, VP5 and VP7. In none of these 219 
cases we were able to rescue stable viruses that could be propagated beyond one passage 220 
after transfection, suggesting that infectious viruses were generated but they were unstable 221 
12 
(data not shown). We sequenced a portion of segments 2 and 6 for all of the reassortants 222 
successfully rescued to confirm the identity of each virus produced. In addition, we 223 
repeated each rescue at least three times independently (using two different plasmid 224 
preparations) in order to rule out that the failure in rescuing certain reassortants was due to 225 
deleterious mutations arising by chance during the rescue experiments.  226 
Replication kinetics of synthetic viruses. Replication kinetics of the rescued synthetic 227 
viruses were assessed in BHK21 cells using a low MOI (0.001) in order to simulate the initial 228 
production of a viral master stock for vaccine production (Fig. 1A).  14 of the 16 synthetic 229 
viruses released virus into the supernatant of infected cells reaching titers higher than 1x104 230 
TCID50 per ml at 72h post-infection. Differences in the replication kinetics between viruses 231 
reaching titers > 106 TCID50/ml at 72h p.i. (e.g. B1BTV-1
VP2-P5, B1BTV-9
VP2/VP5) and those  with 232 
lower titers (<  106 TCID50/ml) were especially evident in the first 24h. Indeed, the titers of 233 
the three reassortants with lower yields at 72h p.i. (B1BTV-2
VP2/VP5 , B1BTV-25
VP2/VP5, and 234 
B1BTV-26
VP2/VP5) increased 10 to 1000 fold by 120 hpi, reaching levels compatible with the 235 
other reassortants produced in this study  (data not shown). 236 
The size of the plaques induced in VERO cells appeared to be largely, but not always, 237 
correlated to the titers reached in replication kinetic assays in BHK21 cells (Fig. 1B).  238 
Vaccination with inactivated synthetic BTV-based vaccines incorporating the BTV-8 VP2 239 
protein confers protection against homologous challenge. In order to validate the use of 240 
synthetic viruses as inactivated vaccines against BTV, we carried out vaccination trials using 241 
B1BTV-8
VP2/VP5 and B1BTV-8
VP2 (Fig. 2). These strains were inactivated with binary 242 
ethyleneimine and prepared in an industrial setting at the Merial S.A.S. laboratory similarly 243 
to the existing inactivated commercial vaccines (30).  244 
For the vaccine trial, sheep were assigned into 4 groups:  an unvaccinated control group 245 
13 
(G1) and three other groups in which animals were inoculated with vaccine preparations 246 
containing identical antigen payload dose to commercial vaccines of B1BTV-8
VP2/VP5 (G2) and 247 
B1BTV-8
VP2 (G3) and a lower antigen dose (1/10th) of B1BTV-8
VP2 (G4). Animals were 248 
subsequently challenged intra-dermally with a virulent BTV-8 strain (Fig. 2 and Table 2). 249 
As anticipated, all six unvaccinated control sheep (G1) showed fever and developed clinical 250 
signs commonly associated with BTV infection. The peak of fever was reached at day 7 post-251 
challenge (41.3 ±0.2oC) in which all animals exhibited congestion of ears, eyes, nostrils and 252 
lips, edema in the lips and erythema (redness of skin). Due to the severity of the clinical 253 
signs, one sheep had to be euthanized at day 10 post-challenge. Viremia was detected 254 
throughout the 14 days in all animals of the group. In sheep vaccinated with B1BTV-8
VP2/VP5 255 
(G2) no increase in rectal temperature was observed in any of the vaccinated animals and 256 
only mild respiratory signs were observed in one animal on days 7 and 8 post-challenge. 257 
Viremia was not detected in any of the animals of this group. 258 
B1BTV-8
VP2 was used in the vaccination of groups G3 and G4. In both vaccination groups, the 259 
presence of BTV-8 VP2 protein prevented fever and viremia. However, one animal in G3 did 260 
not seem to respond to vaccination and exhibited mild clinical signs of infection. Viremia 261 
was observed in this sheep to similar levels observed in the unvaccinated controls. 262 
Interestingly, 4 of the 5 animals in G4 did not develop neutralizing antibodies after 263 
vaccination but were protected against virulent BTV challenge. These data reinforce the idea 264 
that the presence of detectable neutralizing antibodies in vaccinated animal is not 265 
absolutely required for protection against BTV infection. 266 
Synthetic BTVs with a chimeric BTV-1 and BTV-8 VP2 are neutralized by both BTV-1 and 267 
BTV-8 antisera. In addition to using the entire VP2 coding sequence of individual serotypes, 268 
we also tested whether it was possible to generate chimeric VP2 proteins cross-reacting 269 
14 
with different serotypes. To achieve this, we designed a DNA plasmid encoding a chimeric 270 
VP2 protein in which amino acid residues from position 220 to 429 of BTV-1 were 271 
substituted by the homologous region of BTV-8 VP2 (Fig. 3A). The design of this chimera was 272 
based on the presence of conserved residues in the BTV-1 and BTV-8 VP2 junction sites, 273 
while including divergent areas where neutralizing epitopes had been identified in previous 274 
studies (37-40). This novel VP2 segment was processed for reverse genetics and used in the 275 
successful rescue of a synthetic virus termed B1BTV-1
(8-VP2-220-429).  276 
To determine if the introduction of the BTV-8 VP2 region into the BTV-1 VP2 changed the 277 
antigenicity of the resulting chimeric proteins, we carried out virus neutralization assays of 278 
wild type BTV-1, BTV-8 and B1BTV-1
(8VP2-220-429) with sheep antisera raised against BTV-1 or 279 
BTV-8. Unlike parental viruses, which were neutralised only by the homologous antisera, 280 
B1BTV-1
(8VP2 220-429) was cross-neutralized by both BTV-1 and BTV-8 antisera, suggesting that 281 
the design of “bivalent” synthetic viruses is theoretically feasible  (Fig. 3B).  282 
 283 
284 
15 
DISCUSSION 285 
In the present study we devised a novel vaccine platform for the production of inactivated 286 
synthetic viruses which facilitates vaccine production against current and newly emerging 287 
BTV serotypes. Importantly, the ability for these vaccines to be scaled to an industrial scale 288 
has been proven.  289 
Our vaccine platform is based on the design and rescue of viruses containing the VP2 (or 290 
VP2 and VP5) of distinct BTV serotypes with a viral “backbone” already adapted to tissue 291 
culture conditions and vaccine production. We have validated this approach by selecting 292 
two reassortants, B1BTV-8
VP2/VP5
 and B1BTV-8
VP2, which have been prepared in an industrial 293 
setting and proved to protect sheep as effectively as current commercial inactivated 294 
vaccines based upon wild type strains of BTV-8 (30).  295 
If a new outbreak is caused by a currently known BTV serotype, pre-prepared “off-the-shelf” 296 
sBTV viruses, which have been validated for the initial steps of master-stock vaccine 297 
preparation, could be used in an accelerated vaccine production pipeline. In case of an 298 
emerging BTV strain of a previously unknown serotype (or a particularly divergent strain 299 
within a known serotype), the nucleotide sequence of segment 2 (encoding the VP2 protein) 300 
is synthesised and cloned into a DNA plasmid vector which, in parallel with the tissue culture 301 
adapted BTV backbone, is used for the rescue of a replication competent sBTV virus by 302 
reverse genetics (Fig. 4). These vaccines are safe given that the inactivation step eliminates 303 
the risk of releasing replication competent pathogenic viruses into the environment. In 304 
addition, no secondary effects post-vaccination were observed in any of the vaccinated 305 
animals in our trials. 306 
The development of veterinary vaccines from discovery to regulatory approval and their use 307 
in the market is an extremely costly and lengthy process. Hence, vaccines for emerging 308 
16 
diseases, especially if caused by pathogens with multiple distinct serotypes (and therefore 309 
requiring multiple products) are an especially big challenge for industry. In most cases, for 310 
obvious economic reasons, vaccine production initiates only after an outbreak occurs in an 311 
area where there is a potential market. In order to respond to BTV outbreaks, vaccine 312 
manufacturers have been able to significantly reduce the time needed to introduce new 313 
products into the market. However, it can take approximately 1 to 6 months for a vaccine 314 
manufacturer to acquire a new BTV strain from the field and a further 14-20 months to 315 
develop, test, produce a new vaccine and take it through provisional market authorization. 316 
These are conservative figures, and assume that every step runs smoothly, but it does 317 
happen that a seed vaccine strain may not pass all of the many steps required for vaccine 318 
development. Because all of the elements of the vaccines described in this study are derived 319 
synthetically, the acquisition of a viral isolate by industry and many of the quality control 320 
steps required by manufacturers prior to the introduction of field samples into the vaccine 321 
pipeline (e.g. presence of adventitious agents) can be bypassed and/or carried out more 322 
easily. In addition, a deeper understanding of possible barriers regulating reassortment of 323 
different genomic segments between specific BTV serotypes can also result in a further 324 
reduction in the time taken to obtain a new master seed for a new reassortant. Based upon 325 
current industry experience, the synthetic biology approach to vaccine development could 326 
save 6 months across the entire vaccine pipeline.  327 
The timeline of vaccine production can be absolutely critical to halting the spread of a newly 328 
introduced BTV serotype. Most bluetongue outbreaks in temperate regions will have a 329 
limited diffusion in the first vector season after introduction, but will spread considerably 330 
and cause extensive damage in the following year (41).  331 
We have used and tested a single “backbone” in the current study based on BTV-1. It is 332 
17 
likely that other backbones might be useful in order to increase the ability to rescue any BTV 333 
serotype/strain. We failed in the current study to obtain stable synthetic viruses containing 334 
the VP2 of BTV-5, -7, -10, -12, -15, -16, -18, -19. These serotypes don’t seem to have any 335 
particular phylogenetic feature in common that could explain their unsuccessful rescue with 336 
a BTV-1 backbone (Fig. 5). Hence, more studies with additional backbones (or additional 337 
segment 2 sequences) will certainly shed light on the “compatibility” of different BTV 338 
proteins or genomic segments.  339 
To further highlight the possibilities of genome manipulation for vaccine production, we also 340 
designed and rescued a synthetic BTV chimera containing a VP2 protein including regions 341 
derived from both BTV-1 and BTV-8. Interestingly, while the parental viruses were 342 
neutralized only by homologous antisera, the chimeric proteins could be neutralized by both 343 
BTV-1 and BTV-8 antisera. These data suggest that neutralizing epitopes are present in 344 
different areas of the VP2 and likely “bivalent” strains eliciting neutralizing antibodies for 345 
multiple strains can be obtained. Thus, the potential exists to develop products made by 2 346 
or 3 synthetic strains with chimeric VP2 that may be effective against multiple serotypes.  347 
Several potential strategies for vaccination against BTV have been developed in the last 348 
decade (42). In mouse models, immunization with VP2 and VP5 expressed in bacteria has 349 
recently been shown to protect against lethal BTV challenge (43). Mice were also protected 350 
against BTV when VP2 was expressed in vectors such as Bovine herpesvirus 4 (BoHV-4) (44), 351 
Equine herpesvirus 1 (EHV-1) (45) or modified Vaccinia Ankara (MVA) (46).  352 
In sheep, virus-like particles (VLPs) derived using recombinant baculovirus expression 353 
systems have been shown to protect against virulent BTV challenge (47, 48). Vesicular 354 
stomatitis viral replicons expressing VP2 or similar vaccines based on canarypoxviruses have 355 
also been shown to be potentially effective vaccines for bluetongue  (49, 50).   356 
18 
Vaccines based on reverse genetics include the generation of live attenuated vaccines in 357 
which the VP2 and VP5 proteins of BTV-1 and BTV-8 were introduced into an attenuated 358 
BTV-6 backbone (51). Disabled-infectious-single-cycle (DISC) BTV vaccines have also proven 359 
to be effective in experimental trials in sheep. These vaccines are particularly interesting as 360 
they are generated by rescuing BTV in cell lines expressing one of the viral proteins in trans 361 
and therefore might possess most of the benefits of the live attenuated vaccines without 362 
their inherent risks (52). 363 
However, the passage from a potential vaccine developed in an experimental setting to an 364 
industrial product ready to be used in the market is affected by several economic, scientific 365 
and regulatory issues that are particularly complex for emerging diseases. The vaccine 366 
platform that we have developed has the advantage of utilising synthetic biology in order to 367 
curtail the developmental period, whilst simultaneously equating to an existing commercial 368 
product and its known qualities. In turn, this allows the product to be rapidly introduced 369 
into the market when necessary.    370 
 371 
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Table 1. Genbank accession numbers of the BTV viral segments used in this study. 556 
Serotype 
Genbank Accession Number 
Segment 2 Segment 6 
BTV-1  
Backbone
BTV-1 FJ969720 FJ969723
Segment 1 
FJ969719 
 
Segment 3 
FJ969721 
 
Segment 4 
FJ969722 
 
Segment 5 
FJ969724 
 
Segment 7 
FJ969725 
 
Segment 8 
FJ969726 
 
Segment 9 
JN848767 
 
Segment 10 
FJ969728 
 
BTV-2 AJ585123 JN255867 
BTV-3 AJ585124 AJ586697
BTV-4 AJ585125 AJ586699
BTV-5 AJ585126 AJ586700 
BTV-6 AJ585127 AJ586703
BTV-7 AJ585128 AJ586704 
BTV-8 AM498052 AM498056
BTV-9 AJ585130 AJ586708 
BTV-10 AJ585131 AJ586709
BTV-11 AJ585132 AJ586710 
BTV-12 AJ585133 AJ586711 
BTV-13 AJ585134 AJ586713
BTV-14 AJ585135 AJ586714 
BTV-15 AJ585136 AJ586716
BTV-16 AJ585137 AJ586719 
BTV-17 AJ585138 AJ586720
BTV-18 AJ585139 AJ586721 
BTV-18 AJ585140 AJ586722
BTV-20 AJ585141 AJ586723 
BTV-21 AJ585142 AJ586724
BTV-22 AJ585143 AJ586725 
BTV-23 AJ585144 AJ586727 
BTV-24 AJ585145 AJ586730
BTV-25 EU839840 EU839842 
BTV-26 HM590642 JN255159
 557 
 558 
559 
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Table 2. BTV-8 neutralizing antibody response in vaccinated and control sheep.  560 
 561 
 562 
Groups 
Animal 
BTV-8 Neutralizing Antibody Titres* 
Day -21 Day 0 Day 14 
G1 
 
 Unvaccinated 
control 
10349 <0.48 <0.48 0.89 
10372 <0.48 <0.48 1.12 
10375 <0.48 <0.48 2.08 
10412 <0.48 <0.48 1.28 
10434 <0.48 <0.48 n.a. 
20133 <0.48 <0.48 1.20 
Mean ±SD <0.48 <0.48 1.31 ±0.45 
G2 
 
B1BTV-8
VP2/VP5 
10358 <0.48 0.53 2.08 
10376 <0.48 0.80 2.08 
10379 <0.48 0.72 1.76 
10414 <0.48 1.20 1.20 
20152 <0.48 0.72 1.76 
Mean ±SD <0.48 0.79 ±0.25 1.78 ±0.36 
G3 
 
B1BTV-8
VP2 
10348 <0.48 0.72 1.68 
10360 <0.48 0.80 1.85 
10371 <0.48 <0.48 1.76 
10374 <0.48 <0.48 2.16 
10424 <0.48 0.53 1.76 
Mean ±SD <0.48 <0.60 ±0.15 1.84 ±0.19 
G4 
 
B1BTV-8
8VP2  
(Low Dose) 
10356 <0.48 <0.48 1.77 
10363 <0.48 <0.48 2.64 
10385 <0.48 0.72 1.20 
10420 <0.48 <0.48 1.37 
20103 <0.48 <0.48 1.76 
Mean ±SD <0.48 <0.53 ±0.11 1.75 ±0.56 
  
*The neutralizing titre in each sheep was expressed as log10 of 50 per cent protective dose 563 
(PD50). 564 
 565 
 566 
 567 
  568 
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FIGURE LEGENDS 569 
 570 
Figure 1. Replication kinetics and plaque phenotype of synthetic viruses. A. Viral 571 
replication kinetics of synthetic viruses in BHK21 cells. Confluent monolayers were infected 572 
with each sBTV reassortant at a MOI of 0.001 and the virus supernatants titrated as 573 
described in Materials and Methods. B. Morphology of plaques induced by synthetic viruses 574 
in VERO cells. Immunostaining of viral plaques was performed using a BTV-1 VP7 antibody, 575 
followed by a HRP-conjugated secondary antibody and staining with TrueBlue.  576 
Figure 2. Sheep vaccinated with B1BTV-8
VP2/VP5 and B1BTV-8
VP2 are protected against wild 577 
type BTV-8 challenge. Vaccine trials were carried out using four groups of Lacaune 578 
crossbred sheep. Group 1 were not vaccinated while Groups 2 and 3 were  vaccinated with 579 
either B1BTV-8
VP2/VP5 or B1BTV-8
VP2, respectively. An additional group of sheep was also 580 
vaccinated with B1BTV-8
VP2 (Group 4) but with a lower vaccine dose that used in current 581 
vaccine formulations. 21 days post vaccination each group was challenged with a virulent 582 
BTV-8 strain and each animal was assessed for the onset of fever, clinical signs and viremia.  583 
14 of 15 vaccinated animals in groups 2-4 were protected against BTV-8 challenge. One 584 
animal in Group 3 developed fever and displayed viremia.  585 
Figure 3. A synthetic virus with a chimeric BTV-1/BTV-8 VP2 is replication competent and 586 
cross-reacts with BTV-1 and BTV-8 antisera. A. Protein alignment of BTV-1 and BTV-8 VP2. 587 
B. Plaque morphology of parental and chimeric synthetic reassortants (B1BTV-1
(BTV-8-220-429)) 588 
(left). Neutralization assays (right) of BTV-1, BTV-8 and B1BTV-1
(8VP2-220-429) using BTV-1 and 589 
BTV-8 antisera as described in Materials and Methods. BTV-1 and BTV-8 are neutralized only 590 
by homologous antisera. On the other hand, B1BTV-1
(8VP2-220-429) is neutralized by both BTV-1 591 
30 
and BTV-8 antisera. 592 
Figure 4. A vaccine platform based on inactivated synthetic viruses against current and 593 
emerging BTV serotypes. The strategy used for the development of a vaccine platform 594 
based on synthetic reassortants formed by a “backbone” based on cell-culture adapted BTV-595 
1, and the outer core VP2 protein (or VP2 and VP5) of the serotype of interest. “Off-the-596 
shelf“ or newly-obtained vaccine strains will be used for vaccine development depending on 597 
the BTV strain involved in the outbreak to be contained.  598 
Figure 5. Phylogenetic relationships of the genomic segments encoding VP2, VP5 and VP7 599 
of the BTV reference strains. Unrooted maximum likelihood phylogenetic trees of the 600 
genomic segments encoding for VP2, VP5 and VP7 of the BTV reference strains. Trees were 601 
estimated using PhyML (53)  with 1000 bootstraps under the best-fit model of nucleotide 602 
substitution determined using Modeltest (54). Branch lengths are drawn to scale of 603 
nucleotide substitutions per site with the bars representing 0.5 substitution/site. In red are 604 
indicated the serotypes for which we have not been able to rescue stable synthetic viruses 605 
in a BTV-1 backbone.  606 
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